e hyd − (the so-called pre-hydrated/solvated electron, e pre − ) was directly observed (9) (10) (11) . Our careful fs-TRLS measurements (12) led to resolving the long-standing controversies about the lifetime and physical properties of e pre − . After identifying and removal of the coherent 'spike' effect in fs-TRLS measurements, we demonstrated that e pre − has a lifetime of about 500 fs and is a weakly-bound excited state of the well-bound hydrated electron (12) (12) (13) (14) (15) (16) (17) (18) . Previous reviews on ultrafast DET reactions of e pre − with various biological and environmental molecules can be found in refs. (19) (20) (21) .
Through fs-TRLS studies, we found that weakly-bound e pre − plays a key role in IR-induced DNA damage in an aqueous environment. Particularly we discovered that the ultrafast DET reaction of e pre − leads to chemical bond breaks at the guanine base (17) and DNA strand breaks (22) . Our results challenged the conventional notion that damage to the genome by IR is mainly induced by an oxidizing OH • radical, and might lead to improved strategies for radiotherapy of cancer and radioprotection (19, 23) . Moreover, we have recently demonstrated a reductive damaging mechanism in living cells, which may be related to the pathology of diseases, especially cancer (24) .
We also discovered the DET reaction mechanisms of cisplatin as both a widely-used chemotherapeutic drug and a radiosensitizer (14, 15) and of halopyrimidines (XdUs, X=Cl, Br or I) as potential radiosensitizers (13, 16, 18) . Our findings have provided a molecular basis for the success and failure in clinical use/trials of cisplatin and halopyrimidines, respectively.
The integration of fs-TRLS technique with molecular biology and cell biology methods to advance fundamental understanding and therapies of human diseases, notably cancer, might lead to a new transdisciplinary frontier called femtomedicine (FMD) and advances in cancer therapy (19) . Our mechanistic studies in FMD (12) (13) (14) (15) (16) (17) (18) (19) 22) provide remarkable opportunities to improve the therapies of existing drugs and to develop new effective drugs. Indeed, our studies have led to the development of novel cisplatin-based combination therapies that could significantly improve the therapeutic efficacy of cisplatin against human ovarian, cervical and lung cancers (25) . Based on our new understanding of differential intracellular environments between normal and cancerous cells, we have also discovered a new family of non-platinum-based molecules (called FMD molecules) that selectively kill cancer cells and protect normal cells, effective for targeted chemotherapy of multiple cancers (26) .
The newly discovered FMD compounds, such as 4,5-dichloro/dibromo/diiodo-1,2-diaminobenzene (benzenediamine/ phenylenediamine) and 4(3)-chloro/bromo/iodo-1,2-diaminobenzene (benzenediamine/phenylenediamine) (shortened as FMD-nX-DABs or B(NH 2 ) 2 X n with X=Cl, Br or I, and n=1, 2), act essentially as cisplatin analogues, whose molecular structures were reported previously (26) . They are expected to be highly effective in DET reactions with either weakly-bound electrons intrinsic in the more reductive intracellular environment of abnormal (cancer) cells or ultrashort-lived e pre − produced by ionizing radiation of biological systems. The resultant radical [B(NH 2 ) 2 X n-1 ]
• is highly reactive and can effectively lead to DNA damage and cell death. An advantage of these FMD compounds over cisplatin and halopyrimidines (XdUs) is that the DET reaction of FMDs is sufficiently effective but they are far less toxic due to the absence of the heavy metal (Pt). Such FMD compounds alone have shown highly desirable targeting properties as anti-tumor agents for targeted chemotherapy of multiple types of cancer (26) . Moreover, the DET reaction with a FMD molecule will be more effective in the microenvironment of tumor due to its hypoxia, which reduces the competitive attachment of e pre − to oxygen. Thus, the FMD compounds are expected to be effective hypoxic radiosensitizers. This paper presents results of in vitro and in vivo studies of the FMD compounds in combination with ionizing radiation to achieve targeted radiotherapy of human cervical, ovarian, head and neck, and lung cancers.
Materials and Methods
Chemicals and reagents. Details on all the chemicals and reagents used in this study have been given previously (26) . FMD-nX-DABs have excellent solubility of >40 mM in ethanol (EtOH), and limited solubility ranging from 0.1 to 10 mM in MEM (cell culture medium). Thus, their stock solutions in 20 or 40 mM were prepared by dissolving the compounds in pure EtOH. For in vitro cell line experiments, small volumes of the compound stock solutions were added into the culture wells while the vehicle (EtOH) concentration was kept below 1.5%. For in vivo mouse experiments, our studies were focused on FMD-2Br-DAB and its solubility in MEM (cell culture medium) was well determined to be 0.85±0.07 mM by spectrophotometric measurements. The stock solution of FMD-2Br-DAB was diluted in MEM to have 10% ETOH, and 100 μl of the diluted solution was injected into each mouse (~20 g) to make a concentration at 7 mg/kg of FMD-2Br-DAB in mice, corresponding to an estimated in vivo concentration of 0.35±0.03 mM.
Cell lines and culture conditions. In the Waterloo laboratory (24) (25) (26) Medium (Leibovitz) with 10% FBS, respectively. The cells were maintained at 37 °C in a humidified atmosphere containing 5% CO 2 . In the STTARR facility in Toronto, 74B cells were acquired through a generous donation by Dr. Brad Wouters (PMH, UHN) and were cultured in Iscove's MDM media with 10% FBS, while ME180 and A549 cells were obtained from the ATCC directly.
The above-listed cells obtained directly from the CCR or ATCC were passaged in our laboratories for fewer than 6 months after receipt or resuscitation. The CCR performed cell line characterizations by karyotypic and chromosome analyses, while the ATCC performed cell line characterizations by karyotypic analysis, morphology check, isoenzymology and short tandem repeat (STR) analysis (DNA fingerprinting). The 74B cells obtained from Dr. Brad Wouters were tested by mycoplasma testing using PCR and genotyping within 6 months after receipt.
In vitro cell viability and clonogenic assays. The cell growth and survival rates with various treatments were respectively determined by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT) assay (Invitrogen), one of the most commonly used cell viability 6 assays, and the clonogenic assay. The details have been given previously (24) (25) (26) . Briefly, cells were plated at a density of 7×10 3 cells/well in 96-well plates. Following overnight incubation, the culture medium was replaced by fresh culture medium. For in vitro radio-toxicity tests, the cells were incubated for 12 h with varying drug concentrations, then irradiated by 225 kV X-ray (Precision, X-RAD IR 225) at a dose rate of 2 Gy/min with various X-ray doses, and after irradiation, the cells were incubated for 12 days. The MTT assays of cell viability were then conducted. For in vitro tests of the radiosensitizing effects of the FMD compounds, similar MTT assays were conducted at 6 days post-irradiation. For clonogenic assays (24, 27) compound plus IR. The FMD compound at 7 mg/kg was administrated by IP injection into the mice, and at 1 hr after injection, the mice received given doses of X-rays from a X-RAD 225 kV irradiator (Precision X-Ray, Connecticut, USA), either targeted to the tumor or the gut using a collimator. Animals were weighed and flank tumors measured every 2-5 days with calipers; measurements were converted into tumor volume. Growth delay was calculated as the time difference (in days) between treatment and control groups to grow to 1000 mm In vivo radio-toxicity assays in gut, kidney and liver, overall and general toxicity assays. For gut/kidney/liver radio-toxicity assay, the experimental details were given previously (27) . Briefly, SCID and nude mice were irradiated with targeted small intestine radiation at doses of 5, 10, 12, or 15 Gy with and without compound FMD-2Br-DAB at 7 mg/kg. Mice were sacrificed after 72 hours and the small intestine was removed for Ki67 staining. After image staining and scanning, surviving crypts in the intestine were measured compared to those that did not show a positive Ki67 stain. The overall radio-toxicity was assessed through analysis of proteins, enzymes, metabolites, and plasma electrolytes in blood. The mice were treated with 0, 5, 7 mg/kg FMD2Br-DAB daily for 10 days. In addition, to evaluate radiation-induced toxicity therapy, mice were also injected with 0, 5, or 7 mg/kg of FMD and underwent 15 Gy of X-ray radiation at 1 hour after injection, in accordance with the pharmacokinetics data obtained. At the end of treatments, blood samples were collected from the tail vein; if this was not technically possible the saphenous vein was used as an appropriate substitute. These samples were then centrifuged at 13,000 rpm and serum was removed from the mixture. The hepatotoxicity (ALT, ALP, AST), nephrotoxicity (blood BUN, creatinine), and electrolytes (Na, K, etc.) were measured from the samples using an Autoanalyzer (Pulse Instrumentation). Moreover, mice were observed for any general toxicity over the whole period of treatment. These physical indicators included: body weight changes, dull sunken eyes, rapid/shallow breathing, hunched back, and lethargy. Radiation treatment. Irradiations of cells and mice were performed at 225 kV. The X-ray unit at Waterloo (XRAD 225, Precision X-ray, Connecticut, USA) was used for cell and animal irradiations at a dose rate of 2 Gy/min. For in-vivo studies at STTARR (UHN, Toronto), imageguided irradiations were targeted using cone-beam CT guidance (XRAD225Cx, Precision X-Ray, Connecticut, USA) and a 1.0 cm circular collimator (Dose rate: 2.88 Gy/min; parallel-opposed beam geometry). All mice at UHN received a large single dose of 15 Gy, either targeted to the tumor or the gut/kidney/liver using the 1 cm collimator, while the cells and mice in the University of Waterloo were treated with various X-ray doses and multiple fractionated radiation doses (2 Gy ×3), respectively. Statistical analysis. When two groups were compared, the appropriate student's t-test was used.
Multiple groups were compared by ANOVA, extended with an HSD post-hoc test. Statistical analyses were performed using STATISTICA 8 (StatSoft, Tulsa, Ok, USA). A P value <0.05 was considered statistically significant (P*<0.05; **P<0.01; ***P<0.001). In Vitro Radio-Toxicity Tests of FMD-nX-DABs as Novel Radiosensitizers. The in vitro radio-toxicity of FMD-nX-DABs in combination with IR (225 kV x-rays) was investigated in human skin fibroblasts (GM05757). The GM05757 cell line has been widely used as human normal cells in cancer research, particularly in testing new radiosensitizing agents (27) . The cells were treated by FMD-nX-DABs at various concentrations of 0-300/400 μM for 12 hr, followed by various doses of X-ray irradiation. At 12 days post-irradiation, the viability of the cells in 96-well plates was measured by MTT assay. First, the data plotted in Figure 1 show that at zero radiation dose (0 Gy), FMD compounds appeared to have significant 'toxicity', but this was to be expected when the normal cells were incubated with the compounds for 12.5 days (12 hr preirradiation plus 12 days post-irradiation). It was not surprizing that the viability of normal cells decreased with such a long compound incubation time. This is different from the results for normal cells incubated with FMD compounds alone for up to 72 hr, exhibiting little or no effect on the cell viability (26) . Second, Figure 1 interestingly shows that the viability of normal cells pre-treated with FMD compounds up to 400 μM was independent of radiation dose, i.e. no radiotoxicity was observed on normal cells pre-treated with FMD compounds. This is in marked contrast to the results for radiosensitizing effects of FMD compounds on cancer cells (see The in vitro results presented in Figures 1-3 and S1 demonstrate that the presence of a FMD compound enhanced the effectiveness of IR leading to tumor cell death while the compound itself induced no radio-toxicity for normal cells. Thus, the FMD compounds are expected to enhance the effect of IR while inducing minimal or no radio-toxicity in vivo animals.
In Vivo Pharmacokinetic and Radio-Toxicity Studies of FMD-2Br-DAB. The pharmacokinetic (PK) characteristics and in vivo radio-toxicity of a representative FMD agent, FMD-2Br-DAB, in 6-8 week SCID or nude mice are presented in Figure 4 . Figure 4A demonstrates PK profiles of the compound at both the tumor and blood plasma. Significant levels of FMD-2Br-DAB were detected in the plasma, and the highest concentration was observed at about 30 min after i.p. injection and then dropped exponentially with time. For the tumor, the maximum uptake of the compound was observed at ~60 min. We measured the elimination half-life (t 1/2 ) of the FMD compound in plasma to be about 60 min, and given that the plasma volume of a mouse is typically ~50 ml/kg, our estimated clearance (CL) is 
approximately 0.7 ml/hr. These results indicate that the compound has promising pharmacokinetic properties.
FMD-2Br-DAB acute radio-toxicity was first studied in both SCID and nude mouse models through a gut toxicity assay, as described previously (27) . The nude mouse model is more resistant to radiation therapy, and therefore has a larger radio-resistance towards gut toxicity. Figure 4B shows the results of these tests in both SCID and nude mice. The crypt survival was determined through a histological marker Ki67, which marks proliferating cells. Firstly, the results elucidate a decrease in crypt survival in the small intestine (Jejunum and ileum) as the radiation doses increased at 0-15 Gy, consistent with those reported previously (27) . Second, the results show that there was no significant difference in crypt survival rate between irradiated mice in the control and irradiated mice pre-treated with 7 mg/kg FMD-2Br-DAB, indicating that the FMD compound did not enhance radiation-induced gut toxicity (P>0.05). The histological images representing the gut tissues from the irradiated SCID mice are also shown in Figure S2 .
In addition, we studied the acute radio-toxicity of FMD-2Br-DAB in kidney and liver normal tissues. The results are shown in Figures 4C and S3 , which demonstrates no significant difference in Ki67 levels between mice injected with FMD and those with vehicle only for both 0 Gy and 15 Gy irradiation. Although the level of Ki67 increased with radiation, this was expected as after radiation cells begin to repair and proliferate in response to injury. H&E images in Figure S3 show that there was very little or no radiobiological toxicity associated with the FMD compound with and without 15 Gy radiation. These data indicate that the FMD as a novel radiosensitizer is specific to the tumor tissue.
Direct drug (radio-)toxicity was also studied in mice through the overall drug toxicity and general toxicity. FMD-2Br-DAB was administered by IP injection into mice at 0, 5 and 7 mg/kg daily for 10 days, due to the non-toxicity observed in vitro cell line experiments (26) . The results displayed in Table S1 show that the FMD compound (even up to 7 mg/kg/day × 10day) induced no observable overall toxicity, i.e., no hepatotoxicity, no nephrotoxicity, and no changes in electrolytes. Moreover, Table S1 also shows that there were no considerable changes in the overall drug radio-toxicity induced by 15 Gy X-rays between the groups pre-treated with 0, 5, or 7 mg/kg of FMD. Nearly all the measured values were within the normal ranges, except the lower level of globulin. The latter was however also observed in the control group which received no FMD compound/IR. This is attributed to the phenotype of SCID mice employed in the study. Moreover, the survival rate of mice was 100% over a 60 day period with no change in body weight observed ( Figure S4A ), demonstrating that the FMD agent exhibited no general toxicity.
Overall, the substantial in vivo data for toxicity assays in normal tissues and blood shown in Figures 4B, 4C , S2, S3 and S4, together with Table S1 , demonstrate no significant overall, acute and general radiotoxicities (P>0.05), consistent with the in-vitro results in Figure 1 , at the FMD dose levels tested.
In Vivo DNA DSBs and Apoptosis Measurements in IR of a Cervical Cancer Xenograft
Model. The in vivo DNA damage and cell death induced by FMD-2Br-DAB were investigated in a xenograft mouse tumor model of human cervical cancer (ME-180). As shown in Figure 5 , we measured DSBs and apoptosis in tumor tissue, including hypoxic and non-hypoxic regions, at 1 and 24 hrs post-IR of 15 Gy. Figure 5A shows that higher levels of DNA DSBs (γH2AX foci) were observed at 1 hour after the combination treatment of the FMD compound at 7 mg/kg followed by IR (applied 1 hr after drug injection corresponding to the time of highest FMD concentration in the tumor) in the whole tissue including both hypoxic and non-hypoxic regions.
It is seen from Figure 5B that there was a significant (***p<0.001) enhancement in DSBs detected by γH2AX of DNA in hypoxic regions identified by the EF5 hypoxia marker (4) at both 1 and 24 hr post-treatment for the FMD+IR combination. Similarly, Figure 5C shows that there was also an enhancement in the level of the DNA DSB-repair marker at both time-points in the hypoxic areas (53BP1/EF5 double positivity) for the combination treatment ((*p<0.05).
Moreover, a similar enhancement in apoptosis measured by the CC3 marker was observed, as shown in Figure 5D . Histological images corresponding to the results shown in Figures 5A-D are shown in Figures S5 and S6 . These results indicate that the presence of FMD-2Br-DAB enhanced radiosensitivity by increasing DNA DSBs and apoptosis in the tumor, especially in hypoxic regions. As a result, FMD-2Br-DAB can be used as an effective hypoxic radiosensitizer. (***P<0.001). Figure 5F shows that a decrease in vessel density was observed for the combination treatment, compared with the IR alone. Figure 5G shows the relationship between levels of hypoxia following treatment in all 3 tumor models, while Figure 5H shows that Hoechst vessel perfusion was decreased after treatment with the FMD compound plus IR when compared to IR alone. This was also confirmed by DCE MRI Area Under the Curve (AUC) analysis. 
Histological Changes in Xenograft Models
observed results described above. Here, tumor growth inhibition by fractionated radiotherapy using FMD-2Br-DAB was investigated in the xenograft mouse models of human cervical cancer (ME-180) and lung cancer (A549). As shown in Figures 6E and F , certain tumor regrowth delays between the control group, the (7 mg/kg ×3) FMD-2Br-DAB alone, the fractionated radiation (2 Gy ×3) alone and the combination of FMD (7 mg/kg ×3) with radiation (2 Gy ×3) were observed, respectively. The chemotherapeutic effect of the FMD at 7 mg/kg×3 alone was observed, in accordance with the previous study (26) . The combination of FMD with fractionated irradiation enhanced the tumor regrowth delays compared with the radiation alone (**P<0.01), but it is not as significant as the large single dose 15 Gy irradiation ( Figure 6A-C) . No changes in body weight over a 90 day period for all four groups of mice were observed ( Figure S4B ). These results are consistent with the radiosensitizing properties of FMD compounds acting as effective hypoxic radiosensitizers, which may particularly benefit the SABR using large single doses.
Discussion
A practical way to improve the efficacy of radiotherapy is to combine it with a chemical compound (radiosensitizer) (2, 4, 27, 28). Our femtomedicine approach and the discovery of the key role in causing damage to the DNA of e pre − , a novel electron species produced in the radiolysis of water under IR, have offered unique opportunities to improve existing drugs and to develop new effective drugs for high-performance therapy of cancer. Enabled by this innovative strategy and based on the DET mechanism established in our previous studies (12-18, 19, 22) , we have successfully found a series of non-platinum-based halogenated compounds (FMD compounds) as potent anticancer agents (26) and now as hypoxic radiosensitizers.
The present study offers several important observations. First, our in vitro results show that the FMD compounds caused essentially no (radio-)toxicity toward normal cells. These compounds are in contrast to the clinically used Pt-based anticancer drugs, which are highly toxic. Second, our in vitro results show that a FMD compound significantly enhanced the anti-proliferative effects of IR in both cisplatin-sensitive and cisplatin-resistant cancer cells. Enhancements in DNA DSBs in the treated cancer cells were also observed. Thus, these FMD compounds have significant potential as anticancer agents that achieve radiosensitization while inducing no or little systemic toxicity and radio-toxicity. 
Correspondingly, our in vivo results have clearly demonstrated that FMD-2Br-DAB as an exemplary FMD compound combined with IR exhibited minimal (radio-)toxicity in mice, i.e., no overall, acute and general toxicities in normal tissues (gut, kidney and liver) and blood. These results are in good agreement with the in vitro results observed in human normal cells. The observed results also show that the FMD compound is no longer detectable in the blood after 3-4 hours, exhibiting interesting pharmacokinetic properties that could be exploited for improved clinical efficacy.
Furthermore, the in vivo results from the xenograft mouse tumor models of human cervical, head/neck, and lung cancers exhibited significant tumor growth inhibition and regrowth delay due to the radiosensitizing effect of FMD-2Br-DAB combined with a large single dose radiation (15 Gy). Our in vivo results also show that the compound induced significant enhancements in DNA DSBs and apoptosis especially in hypoxic regions, indicating that it is an effective hypoxic radiosensitizer. Moreover, our histological and MRI data also show that FMD in combination with IR led to a decrease in vessel density and an increase in tumor cell death (necrosis).
The radiosensitizing effect of FMD-2Br-DAB combined with multiple small dose fractionated radiation (2 Gy ×3) was also observed, but it was less significant compared with the large single dose of 15 Gy. This is consistent with the properties of FMD compounds as hypoxic radiosensitizers, where reoxygenation between multiple fractionated irradiations reduces the DET reaction efficiency of FMD and the radiosensitizing effect. These results demonstrate that the FMD compound is indeed a novel and effective (hypoxic) radiosensitizer with significant radiosensitizing effect and impact on tumor growth, especially in hypoxic tumor areas. This is of special significance, as there is growing interest in the use of stereotactic ablative radiotherapy (SABR) using large single IR doses in the clinic (28). The presence of tumor hypoxia is a major negative factor in limiting the curability of tumors by SABR at radiation doses that are tolerable to surrounding normal tissues. It has been suggested that this negative effect of hypoxia could be overcome by the addition of a hypoxic cell radiosensitizer at clinically tolerable doses (28).
Compared with clinically available hypoxic cell radiosensitizers, the FMD compounds have a significant advantage that they are essential no toxic even at very high doses, inducing no systemic toxicity in chemotherapy (26) and no radio-toxicity in combination with radiation, as observed in the present study.
The results observed in this study can well be explained by the dissociative-electron-transfer (DET) mechanism established in our previous studies (12) (13) (14) (15) (16) (17) (18) (19) 22) 
